You’re cruising through a renal pharm Q-bank set when a “simple” diuretic question turns into a full-on trap: potassium is high, blood pressure is low-normal, and the stem casually mentions kidney stones. The key to these questions isn’t just knowing the right drug—it’s knowing why every other answer is wrong.
Tag: Renal > Renal Pharmacology & Stones
The Clinical Vignette (Q-bank style)
A 52-year-old man with hypertension and recurrent calcium oxalate kidney stones presents for follow-up. He recently started a new medication. He reports mild dizziness when standing. Labs show:
- Na⁺: 138 mEq/L
- K⁺: 5.8 mEq/L
- HCO₃⁻: 19 mEq/L
- BUN/Cr: mildly increased from baseline
Urinalysis is unremarkable. Which medication most likely caused his current electrolyte abnormality?
Answer choices:
A. Hydrochlorothiazide
B. Furosemide
C. Acetazolamide
D. Spironolactone
E. Mannitol
The Correct Answer: D. Spironolactone
Why it’s correct
This patient has hyperkalemia (K⁺ 5.8) plus a non–anion gap metabolic acidosis pattern suggested by low-ish bicarbonate (common in type 4 RTA physiology). That combination strongly points to reduced aldosterone effect in the collecting duct.
Spironolactone is a potassium-sparing diuretic that:
- Antagonizes the mineralocorticoid (aldosterone) receptor in principal cells
- ↓ ENaC and Na⁺/K⁺-ATPase expression → ↓ Na⁺ reabsorption
- ↓ K⁺ secretion (via ROMK) → hyperkalemia
- ↓ H⁺ secretion indirectly (α-intercalated cell activity falls with low aldosterone effect) → metabolic acidosis
Where it acts (high yield)
- Late distal tubule / collecting duct
- Think: “Aldosterone works here” → so do aldosterone blockers and ENaC blockers.
USMLE buzzwords for K-sparing diuretics
- Hyperkalemia
- Metabolic acidosis
- Often used in:
- Heart failure (mortality benefit with spironolactone/eplerenone)
- Hyperaldosteronism
- Cirrhosis with ascites (spironolactone classically)
- Classic adverse effects:
- Spironolactone: gynecomastia, decreased libido, impotence, menstrual irregularities
- Eplerenone: fewer antiandrogen effects (more selective)
Why the “kidney stone” detail is in the stem
The stem mentions recurrent calcium stones, which should trigger:
Thiazides decrease urinary Ca²⁺ → help prevent calcium stones.
That’s bait. If you reflexively pick hydrochlorothiazide, you miss the actual abnormality: hyperkalemia + acidosis, which thiazides do not cause.
Systematic Distractor Breakdown (why each wrong answer is wrong)
A. Hydrochlorothiazide (Thiazide) — tempting but wrong
Mechanism: Inhibits Na⁺/Cl⁻ cotransporter in distal convoluted tubule.
Expected electrolyte effects:
- Hypokalemia (↑ Na⁺ delivery to collecting duct → ↑ K⁺ secretion)
- Metabolic alkalosis (via volume contraction → ↑ aldosterone)
- Hyponatremia
- Hypercalcemia (↓ urinary Ca²⁺)
Stones tie-in (high yield):
- Thiazides reduce urinary calcium → used for recurrent calcium stones
Why it’s wrong here:
- The patient has hyperkalemia, not hypokalemia.
- Thiazides don’t cause type 4 RTA physiology; they trend alkalotic.
B. Furosemide (Loop diuretic) — wrong direction for calcium and potassium
Mechanism: Inhibits Na⁺-K⁺-2Cl⁻ cotransporter in thick ascending limb.
Expected findings:
- Hypokalemia
- Metabolic alkalosis
- Hypocalcemia (↑ urinary Ca²⁺) and hypomagnesemia
- Ototoxicity risk (esp. with aminoglycosides)
Stones tie-in (high yield):
- Loops increase urinary Ca²⁺ → can worsen calcium stone risk (and cause hypocalcemia)
Why it’s wrong here:
- Again: loop diuretics push toward hypokalemia and alkalosis, not hyperkalemia + acidosis.
C. Acetazolamide (Carbonic anhydrase inhibitor) — acidosis yes, but potassium pattern doesn’t fit
Mechanism: Inhibits carbonic anhydrase in proximal tubule → ↓ HCO₃⁻ reabsorption → bicarbonaturia.
Expected findings:
- Metabolic acidosis (non–anion gap)
- Hypokalemia (increased distal Na⁺ delivery → increased K⁺ secretion)
- Urine becomes alkaline
Stones tie-in (very testable):
- Increases risk of calcium phosphate stones due to alkaline urine (and ↓ citrate handling)
- Also associated with hypocitraturia → less stone inhibition
Why it’s wrong here:
- The patient has hyperkalemia, whereas acetazolamide classically causes hypokalemia.
E. Mannitol (Osmotic diuretic) — wouldn’t selectively cause hyperkalemic metabolic acidosis
Mechanism: Osmotically retains water in the tubule (mainly proximal tubule and descending limb).
Expected clinical uses:
- Reduce intracranial pressure (cerebral edema)
- Reduce intraocular pressure (acute glaucoma)
- Maintain urine flow in rhabdo (conceptually)
Important adverse effect (high yield):
- Can cause pulmonary edema (expands extracellular volume initially)
Why it’s wrong here:
- Mannitol doesn’t produce the characteristic hyperkalemia + type 4 RTA-like acidosis pattern linked to impaired aldosterone signaling in the collecting duct.
Quick Comparison Table (exam-speed recall)
| Drug/Class | Nephron Site | Acid–Base | K⁺ Effect | Ca²⁺ in Urine | Stone Pearls |
|---|---|---|---|---|---|
| Spironolactone / Eplerenone (K-sparing) | Collecting duct | Metabolic acidosis | ↑ K⁺ | No key effect | Think type 4 RTA physiology |
| Amiloride / Triamterene (ENaC blockers) | Collecting duct | Metabolic acidosis | ↑ K⁺ | No key effect | Liddle syndrome tx; lithium DI protection (amiloride) |
| Thiazides | DCT | Metabolic alkalosis | ↓ K⁺ | ↓ Ca²⁺ | Prevent calcium oxalate stones |
| Loops | TAL | Metabolic alkalosis | ↓ K⁺ | ↑ Ca²⁺ | Can worsen Ca stone risk |
| Acetazolamide | PCT | Metabolic acidosis | ↓ K⁺ | (variable) | ↑ Ca phosphate stones (alkaline urine) |
High-Yield “Collector Duct Logic” (how to avoid traps)
When you see hyperkalemia, immediately ask: Is aldosterone low or blocked?
- Aldosterone effect ↓ (Addison disease, ACEi/ARB, heparin, spironolactone/eplerenone)
→ hyperkalemia + metabolic acidosis - Aldosterone effect ↑ (vomiting, diuretics causing volume depletion)
→ hypokalemia + metabolic alkalosis
Also remember:
K-sparing diuretics are weak diuretics—they’re often used to counteract K⁺ loss from loop/thiazides or for specific indications (HF, hyperaldosteronism, cirrhosis).
Rapid-Fire USMLE Pearls (commit these)
- Spironolactone/eplerenone: hyperkalemia, metabolic acidosis, gynecomastia (spirono)
- Amiloride: good for lithium-induced nephrogenic DI and Liddle syndrome
- Thiazides: “stones and bones” (↓ urinary Ca²⁺ → fewer stones; can cause hypercalcemia)
- Acetazolamide: alkaline urine, calcium phosphate stones, used for altitude sickness, glaucoma, idiopathic intracranial hypertension
- Loops: “Loops lose Ca²⁺” (↑ urinary Ca²⁺), ototoxicity, ethacrynic acid if sulfa allergy
Takeaway
This question is designed to reward mechanism-first thinking: hyperkalemia + metabolic acidosis points to collecting duct aldosterone/ENaC blockade—that’s K-sparing diuretics, especially spironolactone in this answer set. The kidney stone detail is there to distract you into thiazides; don’t let a familiar association override the lab pattern.